Pelargonium sidoides extract for treating acute respiratory tract infections
- PMID: 24146345
- DOI: 10.1002/14651858.CD006323.pub3
Pelargonium sidoides extract for treating acute respiratory tract infections
Abstract
Background: Pelargonium sidoides (P. sidoides), also known as Umckaloabo, is a herbal remedy thought to be effective in the treatment of acute respiratory infections (ARIs).
Objectives: To assess the efficacy and safety of P. sidoides for the treatment of ARIs in children and adults.
Search methods: In April 2013 we searched MEDLINE, Journals@Ovid, The Cochrane Library, Biosis Previews, Web of Science, CINAHL, CCMed, XToxline, Global Health, AMED, Derwent Drug File and Backfile, IPA, ISTPB + ISTP/ISSHP, EMBASE, Cambase, LILACS, PubMed component "Supplied by Publisher", TRIPdatabase, the publisher databases: Deutsches Ärzteblatt, Thieme, Springer, ScienceDirect from Elsevier. We conducted a cited reference search (forward) in Web of Science of relevant papers for inclusion. In addition we searched the study registries ClinicalTrials.gov, Deutsches Register klinischer Studien DRKS (German Clinical Trials Register), International Clinical Trials Registry Platform (ICTRP) - WHO ICTRP, Current Controlled Trials and EU Clinical Trials Register.
Selection criteria: Double-blind, randomized controlled trials (RCTs) examining the efficacy of P. sidoides preparations in ARIs compared to placebo or any other treatment. Complete resolution of all symptoms was defined as the primary outcome; in addition, we examined resolution of predefined key symptoms.
Data collection and analysis: At least two review authors (AT, JG, WK) independently extracted and quality scored the data. We performed separate analyses by age group and disease entity. Subanalysis considered type of preparation (liquid, tablets). We examined heterogeneity using the I(2) statistic. We calculated pooled risk ratios (RR) using a fixed-effect model if heterogeneity was absent (I(2) < 5%; P > 0.1), or a random-effects model in the presence of heterogeneity. If heterogeneity was substantial (I(2) > 50%; P < 0.10), a pooled effect was not calculated.
Main results: Of 10 eligible studies eight were included in the analyses; two were of insufficient quality. Three trials (746 patients, low quality of evidence) of efficacy in acute bronchitis in adults showed effectiveness for most outcomes in the liquid preparation but not for tablets. Three other trials (819 children, low quality of evidence) showed similar results for acute bronchitis in children. For both meta-analyses, we did not pool sub totals due to relevant heterogeneity induced by type of preparation.One study in patients with sinusitis (n = 103 adults, very low quality of evidence) showed significant treatment effects (complete resolution at day 21; RR 0.43, 95% confidence interval (CI) 0.30 to 0.62). One study in the common cold demonstrated efficacy after 10 days, but not five days (very low quality of evidence). We rated the study quality as moderate for all studies (unvalidated outcome assessment, minor attrition problems, investigator-initiated trials only). Based on the funnel plot there was suspicion of publication bias.There were no valid data for the treatment of other acute respiratory tract infections. Adverse events were more common with P. sidoides, but none were serious.
Authors' conclusions: P. sidoides may be effective in alleviating symptoms of acute rhinosinusitis and the common cold in adults, but doubt exists. It may be effective in relieving symptoms in acute bronchitis in adults and children, and sinusitis in adults. The overall quality of the evidence was considered low for main outcomes in acute bronchitis in children and adults, and very low for acute sinusitis and the common cold. Reliable data on treatment for other ARIs were not identified.
Update of
-
Pelargonium sidoides extract for acute respiratory tract infections.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006323. doi: 10.1002/14651858.CD006323.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2013 Oct 22;(10):CD006323. doi: 10.1002/14651858.CD006323.pub3. PMID: 18646148 Updated. Review.
Similar articles
-
Pelargonium sidoides extract for acute respiratory tract infections.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006323. doi: 10.1002/14651858.CD006323.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2013 Oct 22;(10):CD006323. doi: 10.1002/14651858.CD006323.pub3. PMID: 18646148 Updated. Review.
-
Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis.Phytomedicine. 2008 May;15(5):378-85. doi: 10.1016/j.phymed.2007.11.023. Epub 2008 Jan 28. Phytomedicine. 2008. PMID: 18222667 Review.
-
EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisited.Curr Med Res Opin. 2018 Mar;34(3):475-485. doi: 10.1080/03007995.2017.1402754. Epub 2017 Dec 8. Curr Med Res Opin. 2018. PMID: 29119837 Review.
-
Pelargonium sidoides root extract for the treatment of acute cough due to lower respiratory tract infection in adults: a feasibility double-blind, placebo-controlled randomised trial.BMC Complement Med Ther. 2021 Jan 29;21(1):48. doi: 10.1186/s12906-021-03206-4. BMC Complement Med Ther. 2021. PMID: 33514367 Free PMC article. Clinical Trial.
-
Effectiveness of Pelargonium sidoides in pediatric patients diagnosed with uncomplicated upper respiratory tract infection: a single-blind, randomized, placebo-controlled study.Eur J Pediatr. 2021 Sep;180(9):3019-3028. doi: 10.1007/s00431-021-04211-y. Epub 2021 Jul 24. Eur J Pediatr. 2021. PMID: 34304301 Clinical Trial.
Cited by
-
Long-term benefits of EPs® 7630 in patients with acute sinusitis: a real-world cohort study.Front Pharmacol. 2024 Mar 18;15:1358879. doi: 10.3389/fphar.2024.1358879. eCollection 2024. Front Pharmacol. 2024. PMID: 38562459 Free PMC article.
-
Editorial: Clinical phytopharmacology.Front Pharmacol. 2024 Jan 15;14:1353483. doi: 10.3389/fphar.2023.1353483. eCollection 2023. Front Pharmacol. 2024. PMID: 38288085 Free PMC article. No abstract available.
-
Stevens' Cure (Umckaloabo)-the vindication of a patent medicine.Front Pharmacol. 2024 Jan 3;14:1294997. doi: 10.3389/fphar.2023.1294997. eCollection 2023. Front Pharmacol. 2024. PMID: 38235116 Free PMC article.
-
Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments.Front Pharmacol. 2023 Sep 28;14:1234701. doi: 10.3389/fphar.2023.1234701. eCollection 2023. Front Pharmacol. 2023. PMID: 37841934 Free PMC article.
-
Mechanistic Evidence of Andrographis paniculata (Burm. f.) Wall. ex Nees, Pelargonium sidoides DC., Echinacea Species and a Combination of Hedera helix L., Primula veris L./Primula elatior L. and Thymus vulgaris L./Thymus zygis L. in the Treatment of Acute, Uncomplicated Respiratory Tract Infections: A Systematic Literature Review and Expert Interviews.Pharmaceuticals (Basel). 2023 Aug 24;16(9):1206. doi: 10.3390/ph16091206. Pharmaceuticals (Basel). 2023. PMID: 37765014 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous